摘要
目的:探索红曲制品导致横纹肌溶解的诊治经验。方法:总结威海市中心医院心血管内科2021年6月收治的1例高龄患者服用红曲制品导致横纹肌溶解的诊疗方案。患者因四肢肌肉疼痛、茶色尿5 d入院,入院当天门诊行生化检查示肌酸激酶:33,257 U/L,结合患者临床表现即可诊断为横纹肌溶解,后给予水化、碱化、保肝等处理,结果:患者经治疗后肌酸激酶迅速降低,肌肉酸痛症状也明显减轻,治疗10 d时患者肌酸激酶已降至正常范围,各生化指标基本正常。已无明显不适感后出院。结论:诊断为横纹肌溶解症后,立即解除致病因素和积极水化、碱化成为治疗的关键。
Objective: To explore the diagnosis and treatment experience of rhabdomyolysis caused by monas-cus products. Methods: The diagnosis and treatment plan of rhabdomyolysis caused by taking monascus products in an elderly patient admitted to the Cardiovascular Department of Weihai Central Hospital in June 2021 was summarized. The patient was admitted to the hospital due to limb muscle pain and brown urine for 5 days. On the day of admission, the biochemical examination in the outpatient department showed that creatine kinase was 33,257 U/L. Combined with the pa-tient’s clinical manifestations and diagnosis of rhabdomyolysis, the patient was given hydration, al-kalization, liver protection and other treatments. Results: The patient’s creatine kinase rapidly de-creased after treatment, and the symptoms of muscle soreness were also significantly alleviated. After 10 days of treatment, the patient’s creatine kinase had fallen to the normal range, and all bi-ochemical indicators were basically normal. He was discharged after no obvious discomfort. Conclu-sion: After diagnosis of rhabdomyolysis, the key to treatment is to immediately remove the patho-genic factors and actively hydrate and alkalize.
出处
《临床医学进展》
2022年第12期11079-11083,共5页
Advances in Clinical Medicine